As well as demonstrating its superior predictive power over the most frequently used classifier or ER, PR, HER2 alone, we also performed additional analyses to make a comparison with ER+ breast cancer classified by hormone receptor (HR) status alone (data not shown). This evidence concerns the gene NR4A1 and breast carcinoma.